Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 18/20 | 0.54 |
| ▸ | JAK2 | O60674 | 18/20 | 0.54 |
| ▸ | CDK2 | P24941 | 14/20 | 0.54 |
| ▸ | TYK2 | P29597 | 11/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 8/20 | 0.52 |
| ▸ | JAK3 | P52333 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676178 | 0.99 | FLT3 (0.55) | FLT3JAK2CDK2TYK2CCNA2 | |
| SCHEMBL13675518 | 0.88 | FLT3 (0.49) | FLT3JAK2CDK2TYK2CCNA2 | |
| SCHEMBL14022774 | 0.86 | JAK2 (0.61) | FLT3JAK2CDK2TYK2CCNA2 | |
| SCHEMBL824025 | 0.85 | FLT3 (0.64) | FLT3JAK2CDK2TYK2CCNA2 | |
| SCHEMBL823837 | 0.83 | FLT3 (0.69) | FLT3JAK2CDK2TYK2CCNA2 | |
| SCHEMBL20322485 | 0.79 | FLT3 (0.82) | FLT3JAK2CDK2TYK2CCNA2 | |
| SCHEMBL823901 | 0.76 | FLT3 (0.78) | FLT3JAK2CDK2TYK2CCNA2 | |
| SCHEMBL24071979 | 0.74 | JAK2 (0.48) | FLT3JAK2CDK2TYK2CCNA2 | |
| SCHEMBL24072371 | 0.74 | FLT3 (0.48) | FLT3JAK2CDK2TYK2CCNA2 | |
| SCHEMBL24071674 | 0.74 | FLT3 (0.48) | FLT3JAK2CDK2TYK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | FLT3 424/4885JAK2 692/4885CDK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.